Arbutus Biopharma Corporation (NASDAQ:ABUS) is set to announce third quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, ABUS to report 3Q20 loss of $ 0.22 per share from revenue of $ 1.66 million.
For the full year, analysts anticipate top line of $ 6.65 million, while looking forward to loss of $ 0.92 per share bottom line.
Previous Quarter Performance
Arbutus Biopharma Corporation reported loss for the second quarter of $ 0.25 per share, from the revenue of $ 1.51 million. According to street consensus, ABUS was expected to report 2Q20 loss of $ 0.24 per share from revenue of $ 1.74 million. The bottom line results missed street analysts by $ 0.01 or 4.17 percent, at the same time, top line results fell short of analysts by $ 0.23 million or 13.22 percent.
Stock Performance
Shares of Arbutus Biopharma Corporation traded up $ 0.17 or 5.88 percent on Wednesday, reaching $ 3.06 with volume of 916.00 thousand shares. Arbutus Biopharma Corporation has traded high as $ 3.09 and has cracked $ 2.87 on the downward trend
The closing price of $ 3.06, representing a 228.41 % increase from the 52 week low of $ 0.88 and a 67.96 % decrease over the 52 week high of $ 9.02.
The company has a market capital of $ 257.26 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Arbutus Biopharma Corporation will be hosting a conference call at 8:45 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.arbutusbio.com
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease.
